Growing urbanization and elevated stress way of living drive the North America SGLT2 inhibitors market

NEW YORK CITY, NY, UNITED STATES, November 26, 2024 /EINPresswire.com/ -- The North America SGLT2 inhibitors market report assesses the competitive scenario of the market, examining all the established players and new market entrants.

𝐓𝐡𝐞 𝐍𝐨𝐫𝐭𝐡 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 𝐒𝐆𝐋𝐓2 𝐈𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐢𝐬 𝐨𝐧 𝐚 𝐠𝐫𝐨𝐰𝐭𝐡 𝐭𝐫𝐚𝐣𝐞𝐜𝐭𝐨𝐫𝐲. 𝐓𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭, 𝐯𝐚𝐥𝐮𝐞𝐝 𝐚𝐭 𝐔𝐒𝐃 7.32 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 2024, 𝐢𝐬 𝐩𝐨𝐢𝐬𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐔𝐒𝐃 16.37 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2034. 𝐈𝐭 𝐢𝐬 𝐚𝐧𝐭𝐢𝐜𝐢𝐩𝐚𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 8.4% 𝐟𝐫𝐨𝐦 2025 𝐭𝐨 2034.

𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧:

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a category of oral prescription medications that are FDA-consented for usage with diet and exercise to lessen blood sugar in grown-ups with type 2 diabetes. Some SGLT2 inhibitors are also FDA consented for usage in people with chronic kidney diseases (CKD) or heart failure to lessen the probability of heart attack involving those people who do not have diabetes.

One kind of SGLT2 inhibitor is now FDA consented to assist in enhancing blood sugar regulation in children 10 years older or even more with type 2 diabetes. Research is ongoing to observe if SGLT2 inhibitors can be of assistance for some kidney illnesses in children who do not have diabetes. The economic variation and residing conditions in urban areas cause heightened rates of obesity, hypertension, diabetes, and kidney illnesses, impacting the North America SGLT2 inhibitors market demand favorably.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐞 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.polarismarketresearch.com/industry-analysis/north-america-sglt2-inhibitors-market/request-for-sample?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01

𝐊𝐞𝐲 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:

• The North America SGLT2 inhibitors market size was valued at USD 7.32 billion in 2024 and is projected to grow to USD 16.37 billion by 2034.

• Escalated blood sugar levels causing a surge in the acquisition of diabetes medicines fuel the need for the SGLT2 inhibitors market in North America.

• The market segmentation is primarily based on indication, drug, distribution channel, and country.

• The study provides market insights into the US and Canada.

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞:

Spearheading market contenders are funding massively in research and development to augment their product lines, which will push the market growth during the forecast period. The top market participants, such as
• AstraZeneca
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Glenmark Pharmaceuticals Ltd.
• Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
• Lexicon Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Sanofi
• Pfizer Inc.

𝐟𝐨𝐜𝐮𝐬 𝐨𝐧 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬 𝐭𝐨 𝐝𝐫𝐢𝐯𝐞 𝐛𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐠𝐫𝐨𝐰𝐭𝐡. 𝐀𝐥𝐬𝐨, 𝐭𝐡𝐞𝐲 𝐥𝐞𝐯𝐞𝐫𝐚𝐠𝐞 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬 𝐭𝐨 𝐢𝐦𝐩𝐫𝐨𝐯𝐞 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐜𝐚𝐩𝐚𝐛𝐢𝐥𝐢𝐭𝐢𝐞𝐬 𝐚𝐧𝐝 𝐝𝐫𝐢𝐯𝐞 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧. 𝐇𝐞𝐫𝐞 𝐚𝐫𝐞 𝐬𝐨𝐦𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐦𝐚𝐣𝐨𝐫 𝐦𝐚𝐫𝐤𝐞𝐭 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬:

• In December 2023, Boehringer Ingelheim acquired European Commission consent for Jardiance (empagliflozin) 10mg and 25mg tablets to be utilized as a supplement to diet and exercise for the cure of deficiently regulated type 2 diabetes mellitus in children ten years or older in the European Union.

• In September 2023, Eli Lilly and Company and Boehringer Ingelheim International GmbH declared that the US FDA has consented to Jardiance (empagliflozin) for its productivity in decreasing the probability of cardiovascular death for heart failure in patients impacted by chronic kidney illnesses.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐚 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐨𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐁𝐞𝐟𝐨𝐫𝐞 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞:
https://www.polarismarketresearch.com/industry-analysis/north-america-sglt2-inhibitors-market/request-for-discount-pricing?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01

𝐆𝐫𝐨𝐰𝐭𝐡 𝐃𝐫𝐢𝐯𝐞𝐫𝐬 𝐚𝐧𝐝 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬:

Progressive Healthcare Framework: An excessively progressive healthcare framework that sanctions speedy and productive handling of diabetes is fueling the North America SGLT2 inhibitors market growth. The region’s reach to progressive medical provision, skilled healthcare exponents and complete healthcare services ascertains that patients are armed with most current treatments involving SGLT2 inhibitors.

Rising Cases of Obesity: Obesity notably increases the probability of advancing type 2 diabetes as a result of progressive body fat, especially around the abdomen, which causes insulin aversion and provocations in controlling blood sugar levels.

Development of SGLT2 Inhibitors: Pharmaceutical firms are organizing the advancement and fostering of SGLT2 inhibitors to oblige the growing aggregate of diabetic patients, especially in the obese community.

𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬:

The US is anticipated to witness a significant CAGR from 2025 to 2034. The country's robust growth is due to its hosting a sizeable pharmaceutical research and developmental zone that has caused the immediate acquisition of contemporary SGLT2 inhibitors and amalgamated therapies.

Canada accounted for the largest share of North America's SGLT2 inhibitors market in 2024. This is primarily because the Canadian government, in association with territorial and local health jurisdictions, has set in motion a gamut of strategies to fight the diabetes outbreak.

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰:

By Indication Outlook
• Cardiovascular
• Chronic Kidney Disease (CKD)
• Type 2 Diabetes
• Others

By Drug Outlook
• Farxiga (Dapagliflozin)
• Inpefa (Sotagliflozin)
• Invokana (Canagliflozin)
• Jardiance (Empagliflozin)
• Qtern (Dapagliflozin/Saxagliptin)
• Other SGLT2 Inhibitors

By Distribution Channel Outlook
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

By Country Outlook
• US
• Canada

𝐈𝐧𝐪𝐮𝐢𝐫𝐞 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐁𝐞𝐟𝐨𝐫𝐞 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞:
https://www.polarismarketresearch.com/industry-analysis/north-america-sglt2-inhibitors-market/inquire-before-buying?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01

Browse PMR's North America SGLT2 Inhibitors Market Report Coverage from Different Publications:
𝐍𝐨𝐫𝐭𝐡 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 𝐒𝐆𝐋𝐓2 𝐈𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐢𝐳𝐞 𝐄𝐱𝐩𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐑𝐞𝐚𝐜𝐡 𝐔𝐒𝐃 16.37 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2034, 𝐆𝐫𝐨𝐰𝐢𝐧𝐠 𝐚𝐭 𝐚𝐧 8.4% 𝐂𝐀𝐆𝐑

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:
Udder Health Market
https://www.polarismarketresearch.com/industry-analysis/udder-health-market

Onychomycosis Market
https://www.polarismarketresearch.com/industry-analysis/onychomycosis-market

DNA and Gene Cloning Services Market
https://www.polarismarketresearch.com/industry-analysis/dna-and-gene-cloning-services-market

Muscle Stimulator Market
https://www.polarismarketresearch.com/industry-analysis/muscle-stimulator-market

Platelet Rich Plasma (PRP) Market
https://www.polarismarketresearch.com/industry-analysis/platelet-rich-plasma-market

𝐀𝐛𝐨𝐮𝐭 𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 & 𝐂𝐨𝐧𝐬𝐮𝐥𝐭𝐢𝐧𝐠, 𝐈𝐧𝐜:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR’s clientele spread across different enterprises. We at Polaris are obliged to serve PMR’s diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR’s customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR’s customers.

Likhil G
Polaris Market Research and Consulting
+ +1 929-297-9727
sales@polarismarketresearch.com
Visit us on social media:
Facebook
X
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.